<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02779959</url>
  </required_header>
  <id_info>
    <org_study_id>30590-01</org_study_id>
    <nct_id>NCT02779959</nct_id>
  </id_info>
  <brief_title>Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT</brief_title>
  <official_title>Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Headache is a common presenting complaint to the emergency department accounting for 1-2% of&#xD;
      patient visits. Of these headaches, approximately 90% are migraine, tension headache, or&#xD;
      combined presentations. The most commonly used migraine therapy in the ED is intravenous&#xD;
      prochlorperazine, but its administration requires close nursing observation, a bed, and the&#xD;
      insertion of an intravenous catheter. Buccal prochlorperazine represents an alternative form&#xD;
      of delivery that enables rapid achievement of therapeutic blood levels and may lead to&#xD;
      symptom resolution. In a randomized, controlled, prospective study,the investigators plan to&#xD;
      assess the efficacy of buccal versus intravenous prochlorperazine for the initial emergency&#xD;
      department treatment of migraine headaches.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in median pian VAS score</measure>
    <time_frame>From Time 0 (baseline) to Time 60 minutes after administration of medication</time_frame>
    <description>Primary end point will be a detectable difference in the median pain VAS score recorded from Time 0 (baseline) to Time 60 minutes (conclusion of the study) for each of the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in median sedation VAS scores</measure>
    <time_frame>From Time 0 (baseline) to Time 60 minutes after administration of medication</time_frame>
    <description>Secondary endpoints will include a detectable difference in median sedation VAS scale from Time 0 (baseline) to Time 60 minutes (conclusion of the study for each of the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in median nausea VAS scores</measure>
    <time_frame>From Time 0 (baseline) to Time 60 minutes after administration of medication</time_frame>
    <description>Secondary endpoints will include a detectable difference in median nausea VAS scale from Time 0 (baseline) to Time 60 minutes (conclusion of the study for each of the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication</measure>
    <time_frame>At the conclusion of the study (60 minutes)</time_frame>
    <description>Comparison between groups for the need for rescue medication as determined by the primary care provider.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up for persistence or recurrence of headache</measure>
    <time_frame>24 -48 hours</time_frame>
    <description>Using a Pain Relief Scale, subjects will be contacted by telephone at 24 - 48 hours after the conclusion of the study and asked to rate their current headache pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>Buccal Prochlorperazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Prochlorperazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prochlorperazine</intervention_name>
    <arm_group_label>Buccal Prochlorperazine</arm_group_label>
    <arm_group_label>Intravenous Prochlorperazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18-65 years of age evaluated in the emergency department at&#xD;
             Harbor-UCLA with migraine headache as defined by the Headache Classification Committee&#xD;
             of the International Headache Society. (Patients must have had at least one prior&#xD;
             similar headache, with or without nausea, vomiting, aura, photophobia, or&#xD;
             phonophobia).&#xD;
&#xD;
          -  Only subjects able to consent to treatment will be included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with the following conditions:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breastfeeding&#xD;
&#xD;
          -  fever greater or equal to 100.4 degrees&#xD;
&#xD;
          -  diastolic blood pressure of 105 or higher&#xD;
&#xD;
          -  altered mental status&#xD;
&#xD;
          -  meningeal signs&#xD;
&#xD;
          -  suspicion for intracranial process requiring further investigation&#xD;
&#xD;
          -  known allergy to prochlorperazine&#xD;
&#xD;
          -  the use of ergotamines, antiemetics, antipsychotics or sedatives in the previous 24&#xD;
             hours of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Tanen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</investigator_affiliation>
    <investigator_full_name>David Tanen</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prochlorperazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 4, 2018</submitted>
    <returned>December 24, 2018</returned>
    <submitted>March 18, 2021</submitted>
    <returned>April 12, 2021</returned>
    <submitted>June 8, 2021</submitted>
    <returned>June 28, 2021</returned>
    <submitted>July 28, 2021</submitted>
    <returned>August 20, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

